BioImagene
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$4.2m | Series B | ||
$26.0m | Series D | ||
N/A | $100m Valuation: $100m | Acquisition | |
Total Funding | AUD46.7m |
Recent News about BioImagene
EditBioImagene operates in the biotechnology sector, specializing in hybridoma technology for DNA modification and GMO research. The company serves clients in the scientific research and agricultural industries, providing advanced technological applications that utilize biological systems and living organisms to create or modify products and processes. BioImagene's business model revolves around offering cutting-edge biotechnological solutions that cater to the needs of researchers and agricultural professionals. Revenue is generated through the sale of proprietary technology, consulting services, and research collaborations.
Keywords: biotechnology, hybridoma technology, DNA modification, GMO research, scientific research, agricultural industry, biological systems, living organisms, proprietary technology, consulting services.